Iron(II) sulfate hydrate

製品番号: HY-W581798: Data Sheet 取扱説明書
FAQs
Technical Support

Iron(II) sulfate hydrate is an iron(II) salt with oral activity, acting as an iron supplier, and is easily oxidized to iron(III) in water. Iron(II) sulfate hydrate induces apoptotic morphological changes in cancer cells, and promotes dose‑dependent iron accumulation in rats. Iron(II) sulfate hydrate can be used in studies of leukemia, breast cancer, iron deficiency, anemia, and restless legs syndrome.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

Iron(II) sulfate hydrate 構造式

CAS 番号 : 17375-41-6

容量		在庫状況
MOQ		Minimum order quantity
50 mg		お問い合わせ
100 mg		お問い合わせ
250 mg		お問い合わせ
Other size		お問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

おすすめ

•関連小分子:

•関連タンパク質:

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

体外実験

Iron (II) sulfate (16-1000 μM; 48 h) hydrate exerts dose-dependent growth inhibition in both K562 and T47D cells, with significant effects in K562 cells at ≥ 63 μM and strong, near-maximal inhibition in T47D cells at 1000 μM.^[1].
Iron (II) sulfate (16-1000 μM; 48 h) hydrate causes a dose-dependent increase in absorbance at 490 nm in a cell-free environment, with significant increases at ≥ 63 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	human chronic myelogenous leukaemia K562 cells, human breast carcinoma T47D cells
Concentration:	16 μM, 31 μM, 63 μM, 125 μM, 250 μM, 500 μM, 1000 μM
Incubation Time:	48 h
Result:	Exhibited a growth inhibitory effect at 16-125 μM. Appeared growth stimulatory at 1000 μM in the MTS assay. Showed a dose-dependent increase in absorbance at 490 nm before adding MTS/PMS after 48 h of incubation.

Cell Cytotoxicity Assay^[1]

Cell Line:	human breast carcinoma T47D cells
Concentration:	1000 μM
Incubation Time:	48 h
Result:	Induced loss of adherent property, cell rounding, and cell shrinkage in T47D cells, indicating cytotoxicity.

体内実験

Iron (II) sulfate (2.84-11.54 mg Fe/kg body weight/day; oral dietary; daily; 31 or 61 days) hydrate accumulates in rat liver, spleen, and kidneys in a dose-dependent manner^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague-Dawley Rats (male, 5-6 weeks old)^[2]
Dosage:	35 mg Fe/kg diet (equivalent to 2.84 mg Fe/kg body weight/day); 70 mg Fe/kg diet (equivalent to 5.69 mg Fe/kg body weight/day); 140 mg Fe/kg diet (equivalent to 11.54 mg Fe/kg body weight/day)
Administration:	oral dietary; daily; 31 or 61 days
Result:	Increased non‑heme iron levels in a dose‑dependent manner in the liver, spleen, and kidneys of rats at 31 and 61 days. Elevated liver non‑heme iron to 67.2, 89.0, and 116.1 μg Fe/g tissue; spleen non‑heme iron to 171.0, 213.0, and 285.6 μg Fe/g tissue; kidney non‑heme iron to 29.0, 30.3, and 31.5 μg Fe/g tissue in low‑, mid‑, and high‑dose groups at 31 days, respectively. Significantly increased mean corpuscular hemoglobin to 1.30 fmol in the high‑dose group compared with the low‑dose group at 31 days. Increased liver non‑heme iron to 105.6, 120.2, and 126.4 μg Fe/g tissue; spleen non‑heme iron to 1018.5, 1107.2, and 1126.4 μg Fe/g tissue; kidney non‑heme iron to 43.5, 49.0, and 48.0 μg Fe/g tissue in low‑, mid‑, and high‑dose groups at 61 days, respectively. Significantly elevated total iron binding capacity to 99.6 mmol/l in the low‑dose group relative to mid‑ and high‑dose groups at 61 days. Maintained plasma iron concentrations within normal ranges and never exceeded 28.8 μmol/l at any dose or duration.

分子量

169.92

分子式

FeH₂O₅S

CAS 番号

17375-41-6

SMILES

O=S(=O)=[Fe](=O)=O.O

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

取扱説明書 (2659 KB)

参考文献

[1]. Kok SH, et al. Paradoxical proliferative potential of iron (II) sulphate on cancer cells after the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. Int J Mol Med. 2007 Jun;19(6):971-5.

[2]. Appel MJ, et al. Disposition, accumulation and toxicity of iron fed as iron (II) sulfate or as sodium iron EDTA in rats. Food Chem Toxicol. 2001;39(3):261-269. [Content Brief]

[3]. Auerbach M, et al. Iron Deficiency in Adults: A Review. JAMA. 2025 May 27;333(20):1813-1823.